Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Schmidt, G.; Gerlinger, Christoph; Juhasz‐Böss, I.; Stickeler, Elmar; Rody, Achim; Liedtke, Cornelia; Wimberger, Pauline; Link, Theresa; Müller, Eberhard; Fehm, Tanja; Abel, Manuela; Stein, Stefan; Bohle, Rainer M.; Endrikat, Jan; Solomayer, Erich‐Franz

doi:10.1007/s00432-016-2146-z

Cited by 13 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of their study revealed that TNBC patients with a HER2/neu score of 0 had a significantly poorer outcome regarding disease-free survival. (Schmidt et al, 2016) Therefore, the identification of HER2 2+ in TNBC patients can play a significant role in the prognosis of this disease, which is a contribution of this study. According to the tumor staging system and the evaluation of the tumor size, lymph nodes involvement, and distant metastasis, it became clear that patients with HER20 had more basal-like behavior and a more aggressive type of tumor; whereas patients with HER 2+ had a less aggressive tumor and mostly were not basal-like tumor.…”

Section: Discussionmentioning

confidence: 82%

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients

Dehghani

Keshavarz

Talei

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer (BC), and its diagnosis is associated with negative expression of hormone receptors and HER2/neu. It consists of 10-20% of all BCs diagnosed. Methods and materials: This study focuses on three groups with different pathology: group one showed complete triple-negative HER2 expression with IHC of BC; groups two and three included patients with ER-, PR-, and HER2 1+ , and ER-, PR-, and HER2 2+ with a negative FISH test. These three groups were compared from the point of prognosis, which consisted of tumor size, patients' age, lymphatic, vascular and perineural invasion, organ metastasis, number of lymph nodes involvement, and the survival rate. Results: A total of 459 TNBC patients were enrolled, of which 268 were placed in the HER2 0 group, 146 in the HER2 1+ group, and 45 in the HER2 2+ group. Distant metastasis and recurrence rate were more common in HER2 0 patients, but bone metastasis was more common in patients with low HER2 expression. All patients with HER2 0 had a smaller tumor size at the time of BC diagnosis in comparison to patients in the low HER2 expression group. Patients with HER2 2+ had less lymphatic and vascular invasion as well as axillary lymph nodes involvement, but larger tumor size at presentation, resulting in a lower rate of recurrence and higher overall survival. Conclusion: The findings revealed that patients with HER2 2+ had better outcome in comparison to the patients with HER2 0 and HER2 1+. Furthermore, the results showed that many patients with HER2 2+ expression were not basal-like and had good prognosis amongst TNBC patients.

show abstract

Section: Discussionmentioning

confidence: 82%

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients

Dehghani

Keshavarz

Talei

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…To date, a number of retrospective studies have explored possible differences in clinical and molecular characteristics between HER2-low and HER2-0 breast cancers. Most studies did not nd different pCR rates as well as survival outcomes between HER2 low expressing breast cancer and HER2-0 breast cancer, only a few studies found differences between the two types and supported HER2-low breast cancer as a separate biological subtype [14][15][16][17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and survival analysis of HER2 negative breast cancer: AR and negative PD-L1 predict worse pathological complete response rate

Zhang,

Yang,

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: HER2-low breast cancer has the potential to emerge as a distinct subtype. Several studies have compared differences between HER2-low and HER2-0 breast cancers, but consensus conclusions have not been reached. Furthermore, a biomarker for predicting pathological complete response (pCR) rates in patients with HER2-low breast cancer remains to be discovered. Method: We collected data of 777 patients from three centers (the Cancer Center of Guangdong Provincial People's Hospital, the Oncology Center of the First Affiliated Hospital of Sun Yat-Sen University and the Sun Yat-Sen University Cancer Center), stratifying them into HER2-low and HER2-0 groups. We compared differences in survival and pCR rates between the two groups and investigated potential biomarkers that could serve as reliable predictors of pCR. Results: The study found higher pCR rates in HER2-0 breast cancers compared to HER2-low tumors (289 patients [30.1%] vs 475 patients [18.1%], p<0.0001). Survival analysis did not show significant advantage for HER2-low tumors over HER2-0 breast cancers. Binary logistic analysis revealed that androgen receptor (AR) expression predicts worse pCR rates in both the overall patient cohort and the HER2-0 breast cancer patient cohort (overall patients: OR: 0.479, 95%CI: (0.250, 0.917), p=0.026; HER2-0 patients: OR: 0.267, 95%CI: (0.080, 0.892), p=0.032). In contrast, programmed death ligand 1 (PD-L1) predicts favorable pCR rates in the overall patient cohort (OR: 3.199, 95%CI: (1.020, 10.037), p=0.046). Conclusion: There is insufficient evidence to classify HER2-low breast cancer as a new subtype. Our study revealed that AR expression, along with negative PD-L1 expression, contributes to poorer pCR outcomes.

show abstract

“…A score of 3+ by IHC was considered as positive and it shows circumferential homogenous dark staining in >10% of the tumor cells. 14…”

Section: Methodsmentioning

confidence: 99%

Expression of anaplastic lymphokinase and HER2/neu immunostaining in patients with breast carcinoma

Ali¹,

Qureshi²,

Fahim³

et al. 2018

Int J Res Med Sci

View full text Add to dashboard Cite

Background: The diagnosis and prognosis of breast cancer is done with various immunomarkers including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2/neu), and Ki-67. The diagnostic utility of Anaplastic Lymphokinase (ALK) and HER2/neu should be explored for better management of breast carcinoma patients. So, the present study was designed to determine the expression of immunostaining with ALK and HER2/neu in patients with breast cancer and to compare the association of ALK expression and HER2/neu with clinicopathological parameters.Methods: This is a cross sectional multicenter study carried out from October 2016 to March 2017. A total of 140 subjects having breast carcinoma by using non-probability purposive sampling technique were selected. After taking informed consent, tissue samples were taken from received specimen of mastectomy for hematoxylin and eosin stain. The immunohistochemistry for ALK and HER2/neu were assessed on the paraffin blocks of the tumor.Results: Out of total 140 cases invasive ductal carcinoma (89%), invasive lobular carcinoma (8%), invasive medullary carcinoma (2.1%) and papillary carcinoma (0.7%) were seen. ALK expression was positive in 81 patients (58%) while HER2/neu expression was positive in 53 cases (38%). Significant association was observed between ALK expression with histological grade, lymph node involvement, skin involvement and necrosis. There was also a significant association was seen between HER2/neu expression with lymph node metastasis and necrosis.Conclusions: Present study shows higher expression of ALK when compared to HER2/neu expression in breast cancer patients.

show abstract

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Abstract: The Her2-neu score 0 might be considered as an innovative prognostic factor for patients with TNBC indicating poor clinical outcome.

Cited by 13 publications

References 40 publications

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients

Clinical characteristics and survival analysis of HER2 negative breast cancer: AR and negative PD-L1 predict worse pathological complete response rate

Expression of anaplastic lymphokinase and HER2/neu immunostaining in patients with breast carcinoma

Contact Info

Product

Resources

About